(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 August 2013 (29.08.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/126636 A1

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61K 31/52* (2006.01)
A61K 31/437 (2006.01) *A61K 31/522* (2006.01)
A61K 31/4985 (2006.01) *A61K 31/53* (2006.01)
A61K 31/517 (2006.01) *A61K 31/706* (2006.01)
A61K 31/519 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2013/027235

(22) International Filing Date:
22 February 2013 (22.02.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/603,012 24 February 2012 (24.02.2012) US
61/716,424 19 October 2012 (19.10.2012) US
61/725,805 13 November 2012 (13.11.2012) US

(71) Applicant: **SIGNAL PHARMACEUTICALS, LLC** [US/US]; 10300 Campus Point Drive, Suite 100, San Diego, CA 92121 (US).

(72) Inventors: **XU, Shuichan**; 12426 Dormouse Road, San Diego, CA 92129 (US). **HEGE, Kristen, Mae**; 616 Howard Ave., Burlingame, CA 94010 (US). **TRAN, Tam, Minh**; 9435 Maler Road, San Diego, CA 92129 (US).

(74) Agents: **INSOGNA, Anthony, M.** et al.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

(54) Title: METHODS FOR TREATING NON- SMALL CELL LUNG CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY

(57) Abstract: Provided herein are methods for treating or preventing advanced non-small cell lung cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of erlotinib or a cytidine analog to a patient having advanced non-small cell lung cancer.




FIG. 1

WO 2013/126636 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*